BioSpace News Archive

Drug Development

MMJ PhytoTech Ltd PhytoTech Therapeutics Phase II Clinical Trial Update

MMJ PhytoTech is pleased to advise that it has received results from the first 10 patients who participated in the Phase 2 clinical trial undertaken by MMJ PhytoTech.

January 31, 2018
·
5 min read
Business

Siemens Healthineers Enlists Former Abbott Vascular Exec to Lead Diagnostics Biz

Nath succeeds Franz Walt, who served as President from 2014-2017.

January 31, 2018
·
2 min read
NUHS Release: Researchers Discover Molecular Nets Inside Heart Muscles Which Hold Promise for New Heart Failure Treatment

The discovery was made jointly by the NUHS, GIS and the NUS Yong Loo Lin School of Medicine, and is now published in Circulation, a journal from the American Heart Association.

January 31, 2018
·
2 min read
Drug Development

Dermira Initiates Phase IIb Dose-Ranging Study Evaluating Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis

The Phase 2b study is designed to evaluate the safety and efficacy of lebrikizumab as a monotherapy.

January 31, 2018
·
10 min read
Biotech Bay

Kalytera Announces Grant of Stock Options

The stock options have an exercise price of $0.38 per common share and expire ten years from the date of grant.

January 31, 2018
·
3 min read
BioMidwest

Skyline Medical Projects 100 STREAMWAY System Sales in the U.S. in 2018

2018 projection would represent a 10x increase over 2017 sales.

January 31, 2018
·
6 min read
CollPlant Announces ADS Listing on NASDAQ

Trading commenced on Wednesday, January 31, 2018 under the ticker symbol “CLGN”.

January 31, 2018
·
4 min read
Genetown

resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The shares commenced trading on the NASDAQ Global Select Market on January 26, 2018 under the ticker symbol “TORC.”

January 31, 2018
·
2 min read
Biotech Bay

iHear Medical Announces FSA Eligibility for the First and Only FDA-Cleared Home Hearing Screener

Offering FSA reimbursement eligibility furthers iHEAR’s mission to provide consumers with affordable and accessible hearing solutions.

January 31, 2018
·
3 min read
Policy

Alkermes Submits NDA to U.S. FDA for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder

The NDA submission is based on a comprehensive clinical efficacy and safety package with data from more than 30 clinical trials and more than 1,500 patients with MDD.

January 31, 2018
·
5 min read